Company Overview and News

Vilas Fund, LP Q1 '18 Letter To Partners - #28 Since Inception, Long Pharma

17h seekingalpha
The performance of the Vilas Fund, LP, the S&P 500 and applicable HFR Index, as of March 31, 2018, follows:
Upvote Downvote

Implied Volatility Surging for Valeant (VRX) Stock Options

2018-04-19 zacks
Investors in Valeant Pharmaceuticals International, Inc. (VRX - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Apr 20, 2018 $17 Call had some of the highest implied volatility of all equity options today.
Upvote Downvote

Schilit, Financial Shenanigans, 4th Ed.

2018-04-18 seekingalpha
It has been 25 years since Howard M. Schilit first published Financial Shenanigans: How to Detect Accounting Gimmicks and Fraud in Financial Reports. And it has been eight years since I reviewed the third edition of the book, starting, and hopelessly dating, my post with the words: "with Jeff Skilling (and now Richard Scrushy) back in the news…." It seems like a lifetime ago. But, alas, financial shenanigans never go out of style.
Upvote Downvote

American Airlines Is A Buy - Cramer's Lightning Round (4/12/18)

2018-04-13 seekingalpha
Cramer took a controversial view on Valeant, saying he would not be a seller at $16.
Upvote Downvote

Asbestos in Talc Products Verdict Means J&J, Imerys Owe Millions - Bloomberg

2018-04-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

It's Time to Shop Shopify Inc Stock Now! | InvestorPlace

2018-04-10 investorplace
History may not repeat, but if it rhymes it’s a great time to buy Shopify Inc (NYSE:SHOP). However, for bullish investors looking for an added layer of support and security above and beyond what you’ll find off and on the Shopify stock chart, a bull call spread is a smarter play. Let me explain.
Upvote Downvote

Sequoia takes Facebook stake as shares slide in data controversy

2018-04-09 livemint
New York: The $4.2 billion Sequoia Fund bought a small position in Facebook Inc. as the stock slid late in the first quarter, investment manager Ruane, Cunniff & Goldfarb told clients.
Upvote Downvote

Valeant Pharmaceuticals’ Branded Rx Segment Performance in 4Q17

In 4Q17, Valeant Pharmaceuticals International’s (VRX) Branded Rx segment generated revenues of $602 million compared to $745 million in 4Q16. That was a 19% decline on a YoY (year-over-year) basis and a 5% decline quarter-over-quarter.
Upvote Downvote

Valeant Pharmaceuticals’ Performance in 4Q17 and 2017

In 4Q17, Valeant Pharmaceuticals International (VRX) generated revenues of $2.2 billion compared to $2.4 billion in 4Q16, which reflected a 10% decline on a YoY (year-over-year) basis and a 3% decline quarter-over-quarter.
Upvote Downvote

When These New Pharma Bros Show Up, Drug Prices Tend to Go Monumentally Higher - Bloomberg

2018-04-06 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis

2018-04-06 globenewswire
WALTHAM, Mass., April 06, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), today announced completion of patient enrollment for the pivotal Phase 3 clinical study of its EGP-437 combination product for the treatment of non-infectious anterior uveitis.
Upvote Downvote

Ackman Is Abandoned by Big Pershing Square Investors - Bloomberg

2018-04-05 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

J&J Jury Set to Weigh Banker's Claims Baby Powder Caused Cancer - Bloomberg

2018-04-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

Deutsche Bank Out With New Top Stock Buys for the Next Year

2018-04-04 247wallst
With the first quarter of 2018 over, and a rash of earnings reports ready to hit the tape, many of the top firms we cover here at 24/7 Wall St. are making some changes to their lists of top stocks to buy. With the markets continuing to experience rising volatility, it makes sense for the big banks and investors to review their ideas and the thesis behind them, and to make changes, which could include taking off both winners and losers.
Upvote Downvote

Why Is Valeant (VRX) Up 4.3% Since Its Last Earnings Report?

2018-04-02 zacks
It has been about a month since the last earnings report for Valeant Pharmaceuticals International, Inc. (VRX - Free Report) . Shares have added about 4.3% in that time frame.
Upvote Downvote

VRX: Valeant Pharmaceuticals International Stock Analysis and Research Report

2017-09-28 - Asif

Valeant Pharmaceuticals International, Inc. is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. We are diverse not only in our sources of revenue from our broad drug and medical device portfolio, but also among the therapeutic classes and geographies we serve. We generated revenues of $4,342 million and $4,792 million for the six months ended June 30, 2017 and 2016, respectively. Our portfolio of products falls into three reportable segments: (i) Bausch + Lomb/International, (ii) Branded Rx and (iii) U.S. Diversified Products. The Bausch + Lomb/International segment consists of: (i) sales in the U.S. of pharmaceutical products, OTC products a...

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 91911K102